Now I have enough calibration context. Let me synthesize the final review.

## Summary

MOCHA (Multi-sample Omics Cohorts with Human Annotation) is a curated resource that aggregates 10 publicly available spatially resolved transcriptomics (SRT) datasets, each paired with expert pathologist annotations, to support multi-sample SRT method development and evaluation. The paper describes the cohort selection, provides an overview of preprocessing and batch correction strategies, and reviews three multi-sample clustering methods (BayeSMART, BASS, STAGATE) that could be applied to the data.

## Strengths

- **Addresses a genuine gap**: Multi-subject SRT datasets with expert annotations are indeed limited, and the need for such resources to benchmark multi-sample integration methods is well-identified. Having these datasets organized in one place with standardized formats does provide practical utility.

- **Diverse cohort coverage**: The 10 cohorts span multiple cancer types, two species, and two technology platforms (10x Visium, ST), with a range of scales from 3 to 94 samples, enabling evaluation of method performance across tissue types, technologies, and sample sizes.

- **Sensible selection criteria**: Requiring expression matrices, spatial coordinates, H&E images, and pathologist annotations for inclusion is well-motivated for the stated goal of spatial domain identification benchmarking.

- **Helpful methodological overview**: Sections 3–4 summarize standard preprocessing pipelines and multi-sample clustering methods, which can orient newcomers to the field.

## Weaknesses

### Major:

- **No empirical demonstration of the resource's utility.** The paper's central claim is that MOCHA "enables" and is "for developing and evaluating multi-sample SRT methods," but it provides zero experimental evidence to support this. No method (not even one of BASS, BayeSMART, or STAGATE, which the paper itself reviews) is run on MOCHA data, no clustering metrics (ARI, NMI, etc.) are reported against the expert annotations, and no batch effect analysis is conducted. For a resource paper claiming to serve as an evaluation benchmark, this is a critical gap—without baseline results, users cannot assess whether MOCHA actually poses the claimed challenges or whether the annotations are reliable ground truth.

- **Underspecified and unchecked annotation harmonization.** The paper groups heterogeneous pathologist labels into four broad categories (immune, stroma, tumor, normal) across cancer cohorts—a key design choice for cross-cohort evaluation—but provides no details on how this mapping was performed, how tissue-specific or ambiguous labels were handled, and no validation (inter-annotator agreement, label frequency analysis, spatial coherence checks) that these categories are consistently applicable. For non-cancer datasets (DLPFC, MOB), the relationship to these four categories is entirely unaddressed. If the label harmonization is ad hoc or lossy, the benchmark's ground truth may be misleading.

- **Unclear differentiation from existing repositories.** The paper cites five existing SRT databases (SORC, Aquila, SODB, STOmicsDB, SpatialDB) but never specifies what MOCHA provides that they lack beyond "expert annotations" and "multi-sample organization." Without a comparison table or clear articulation of the unique value proposition, it is hard to assess whether MOCHA meaningfully advances beyond these existing resources.

### Minor:

- **Sections 3–4 are literature review rather than resource specification.** The preprocessing and method summaries (~2 pages) describe existing tools without connecting them to specific recommendations or evaluations on MOCHA data. This creates the impression of padding rather than substantive contribution. These sections would be more valuable if they included even minimal experimental guidance (e.g., "we recommend Harmony after HVG selection for Visium data because…").

- **Missing resource infrastructure details.** The paper claims "standardized data organization, efficient storage formats" and "formats readily usable with Python and R" but never specifies these (AnnData? Seurat objects? HDF5?). No repository URL, license information, or data access protocol is provided. For a resource paper, these details are essential for adoption and reproducibility.

- **Small cohorts limit multi-sample evaluation.** KC TLS (3 subjects) and LC TLS (5 subjects) have very few samples for meaningful multi-sample integration evaluation, and MOB has only 1 subject, making multi-sample analysis impossible for that cohort. The paper does not discuss these limitations or their implications for benchmark design.

- **Technology homogeneity.** The introduction highlights MERFISH and STARmap as important platforms, yet all 10 MOCHA cohorts use either 10x Visium or the older ST platform—no imaging-based SRT data is included. This limits the resource's applicability to the growing high-resolution spatial omics landscape.

### Trivial:

- Minor redundancy in references (two versions of Stahl et al. 2016).

## Nice-to-Haves

- Run at least 2–3 existing multi-sample methods on the MOCHA cohorts and report ARI/NMI against expert labels—this would transform the paper from a catalog into a usable benchmark.
- Provide a supplementary table showing the raw annotation categories per cohort and their mapping to the four-group scheme, along with label frequency and spatial coherence statistics.
- Add a discussion section covering limitations (cohort size heterogeneity, technology bias, annotation granularity) and a brief future directions plan.
- Specify data formats, distribution URLs, and licensing in the paper.

## Removed Points

- **"No new data generation, no new annotation effort"**: The paper explicitly states these are curated from publicly available datasets with pathologist annotations; claiming novelty from new data generation is not necessary for a resource paper—the value, if any, is in curation, standardization, and benchmarking. However, the lack of new annotations IS a valid concern insofar as it limits incremental contribution.
- **"Sections should be condensed"**: This is a formatting/style nitpick. Removed per instructions.
- **"No repository URL or license"**: This borders on reproducibility nitpick for a double-blind submission (URLs are typically removed). However, the lack of ANY specification of data formats (not just URLs) is kept as a minor weakness above.
- **"Demand for inter-annotator agreement"**: While important, demanding inter-annotator agreement when the annotations come from the original studies' pathologists (not MOCHA's own labeling effort) may be outside the paper's scope. I've kept the concern about annotation transparency but weakened the demand for formal agreement statistics.
- **"No discussion section"**: This is essentially a formatting concern. Removed.

## Novel Insights

The most striking observation across all reviews is that MOCHA occupies an uncomfortable middle ground: it is not a methods paper (no new algorithms), and it is not a fully realized benchmark paper (no experimental evaluation, no baseline results, no annotation validation protocol). For it to succeed as either contribution type, it must deliver on its core promise—if the value proposition is "enabling evaluation," then evaluation must actually be demonstrated. The paper's strongest potential contribution—the harmonized annotations across cohorts—is precisely the part that is most underspecified, creating a gap between the stated mission and the evidence provided.

## Suggestions

- **Run baseline experiments**: Even a simple experiment (e.g., run BASS and STAGATE on 2–3 MOCHA cancer cohorts, report ARI/NMI against the four-category labels) would substantively transform the contribution from catalog to benchmark.
- **Document the annotation mapping fully**: Provide a complete mapping table (original label → four categories) per cohort, ideally with frequency distributions and spatial maps, to validate the harmonization scheme.
- **Specify the data infrastructure**: At minimum, describe the data model (AnnData/Seurat object structure, which slots hold expression/coordinates/images/annotations), how gene identifiers are harmonized, and whether counts are raw or normalized.

## Evaluation

**Originality**: Low. The paper curates existing public datasets with existing annotations and repackages them with minimal new standardization. No new methodology, no new annotations by the authors, and no new evaluation framework.

**Importance of research question**: Moderate. Multi-sample SRT benchmarking is a genuine need, but the paper does not convincingly fill it.

**Claims well-supported**: Weak. The central claim that MOCHA enables method evaluation is unsubstantiated without baseline experiments. The annotation harmonization is asserted but not documented or validated.

**Experimental soundness**: Poor. There are no experiments.

**Clarity**: Moderate. The paper is clearly written but incomplete—lacks a discussion, and key details about the resource itself are missing.

**Value to community**: Potentially moderate if baseline experiments and full documentation were added, but currently limited.

## Score Calibration

Compared against similar dataset/benchmark papers:
- **BMAD** (benchmark paper, no novelty, all existing data): scores 3, 3, 5, 6 → rejected
- **BoneMet** (dataset paper with some benchmarks/experiments): scores 5, 6, 5, 8 → accepted poster
- **ADOPD-Instruct** (dataset paper with experiments but weak novelty): scores 5, 3, 5, 5 → rejected
- **MolTextQA** (dataset paper with benchmarks): scores 3, 8, 6, 3 → withdrawn
- **OMG dataset** (large-scale dataset + trained model): scores 5, 8, 6, 5 → accepted poster
- **GeST/Spotscape** (SRT method papers): scores 3–6 range → rejected

MOCHA shares the weakest aspect of BMAD and MolTextQA—it aggregates existing data without demonstrating new utility through experiments. However, it lacks even the benchmarking experiments that BMAD and MolTextQA at least attempted. The paper's primary claim (enabling evaluation) is entirely prospective. This places it below BMAD (which did run evaluations) and well below OMG and BoneMet (which both included novel experiments). I rate it slightly above a pure catalog with zero analysis because the curation criteria and multi-sample focus do address a real need.

MY FINAL SCORE: <pineapple>3</pineapple>
MY FINAL DECISION: <orange>Reject</orange>